and Objective: V-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations occur in approximately 2-4% of patients with non-small cell lung cancer (NSCLC). BRAF non-V600E mutant NSCLC is a rare entity that has yet to be fully characterized. The treatment paradigm is evolving and is currently often extrapolated from data pertaining to V600E mutations. This article serves as a comprehensive review of the clinical characteristics, prognosis, current management and treatment algorthim for

more »

... ts with NSCLC that harbors BRAF other than the common V600E mutation (non-V600E). Methods: We performed a review of publications on EMBASE and MEDLINE/PubMed that described the prevalence and characteristic features of this patient subset of NSCLC, with a focus on the current treatment landscape, through October 2021. Non-English publications were excluded. We searched ClinicalTrials.gov for active and past trials pertaining to this patient subset.